BOTHELL, Wash., April 7, 2022 /PRNewswire/ -- BioLife Solutions, Inc. /zigman2/quotes/207858501/composite BLFS +4.19% ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, today announced that its Audit Committee (the "Committee") approved the engagement of Grant Thornton LLP ("Grant Thornton") as the Company's new independent registered public accounting firm, effective April 6, 2022. The Company dismissed its prior registered independent public accounting firm following its request for proposal process in connection with the audit for the fiscal year ending December 31, 2022.
On April 7, 2022, the Company filed a Form 8-K describing in further detail the determinations of the Committee described herein in accordance with Form 8-K and the rules and regulations described therein.
About BioLife Solutions
BioLife Solutions is a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets. Our tools portfolio includes our proprietary CryoStor® and HypoThermosol® biopreservation media for shipping and storage, the ThawSTAR ® family of automated, water-free thawing products, evo ® cold chain management system, high capacity cryogenic storage freezers , Stirling Ultracold mechanical freezers, SciSafe biologic storage services, and Sexton Biotechnologies cell processing tools. For more information, please visit www.biolifesolutions.com , www.scisafe.com , www.stirlingultracold.com , or www.sextonbio.com and follow BioLife on Twitter .
Media & Investor Relations
At the CompanyTroy Wichterman
Chief Financial Officer
InvestorsLHA Investor Relations
SOURCE BioLife Solutions, Inc.
Is there a problem with this press release? Contact the source provider Comtex at email@example.com. You can also contact MarketWatch Customer Service via our Customer Center.
Copyright (C) 2022 PR Newswire. All rights reserved